Immuneering Corporation (Nasdaq: IMRX) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide standalone fourth-quarter results. Immuneering is a clinical-stage oncology company with no approved products and no product-sales revenue.
Business context and pipeline
- Lead candidate IMM-1-104 began dosing in a Phase 1/2a trial in November 2022 for advanced RAS-mutant solid tumors. It was in dose escalation at year-end.
- IMM-6-415 remained in IND-enabling studies; management planned to submit an IND in the fourth quarter of 2023.
- The company narrowed its early-stage focus: it paused covalent MEK and PI3K programs and suspended neuroscience programs, prioritizing oncology.
- Computational biology services and external biosample storage were wound down; the remaining contracts were completed during 2022.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0.317 million | $2.080 million |
| Gross profit | $0.159 million | $0.927 million |
| Research and development expense | $36.267 million | $26.541 million |
| General and administrative expense | $15.607 million | $8.272 million |
| Loss from operations | $51.745 million | $33.886 million |
| Net loss | $50.514 million | $33.536 million |
| Basic and diluted net loss per share | $1.91 | $2.46 |
| Net cash used in operating activities | $44.101 million | $30.851 million |
- Revenue fell 84.8%, primarily because the services business was wound down. R&D expense rose 36.6%, and G&A expense rose 88.7%, reflecting increased staffing, stock compensation, professional fees and facilities costs.
- Gross margin was approximately 50% in 2022 versus 45% in 2021; revenue was small and largely services-related.
- At year-end, cash and cash equivalents were $72.637 million and marketable securities were $32.888 million, totaling approximately $105.5 million. Management estimated these resources would fund operations into the fourth quarter of 2024, subject to assumptions and potentially faster cash use.
- Cash and marketable securities decreased from approximately $150.2 million at year-end 2021 to $105.5 million at year-end 2022. Investing cash flow was a net $41.831 million provided, principally reflecting maturities of marketable securities offset by purchases.
- The company reported $12.517 million of total liabilities, including $4.842 million of lease liabilities; the filing reports no debt borrowings. Total current assets were $108.747 million and current liabilities were $8.054 million.
- Accumulated deficit was $109.787 million. No income tax benefit or expense was recorded in 2022. The independent auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting.
Outlook, risks and notable items
- Management expected initial IMM-1-104 pharmacokinetic and safety data in mid-2023, additional PK, safety and initial pharmacodynamic modeling data in the second half of 2023, and—depending on Phase 1 results—Phase 2a initiation in mid-2024. These are forward-looking plans, not reported outcomes.
- The company expects losses and R&D spending to continue increasing and does not expect product revenue for several years, if ever. It may need substantial additional capital; no committed external funding source was disclosed.
- Principal risks include clinical and regulatory failure or delay, safety findings, enrollment and manufacturing challenges, reliance on CROs and other third parties, uncertain platform and preclinical translation, competition, limited patent protection, and potential dilution or less favorable financing terms.
- Management stated there was no substantial doubt about the company’s ability to continue as a going concern, based on its estimate that available resources would cover at least 12 months from issuance of the financial statements.
- The company had no material legal proceedings and reported no material off-balance-sheet arrangements. It had an at-the-market equity program permitting up to $50 million of gross sales; no shares were sold under it in 2022.
Important facts for investors to verify
- Actual IMM-1-104 trial enrollment, dose escalation, safety, PK/PD findings and subsequent development timing.
- Whether IMM-6-415’s planned IND submission and clinical development milestones were achieved.
- Cash burn, investment balances, lease obligations and the assumptions underlying the stated runway into Q4 2024.
- Whether additional financing is needed, and any resulting dilution or changes to planned research programs.
- Whether early clinical results support the company’s preclinical efficacy and tolerability claims; those preclinical results are not proof of benefit in patients.
- The status and scope of patent applications for the lead candidates and the impact of discontinued service revenue on future funding needs.